Bimekizumab (Bimzelx) for Psoriasis

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2024 . Peer-reviewed

Data sources: Crossref

The Medical Letter on Drugs and Therapeutics

Article . 2024

Data sources: Europe PubMed Central

Bimekizumab (Bimzelx) for Psoriasis

descriptionPublicationkeyboard_double_arrow_right Article 22 Jan 2024Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 66, pages 11-13 (eissn: 1523-2859,

Copyright policy )

doi: 10.58347/tml.2024.1694b

pmid: 38212257

Bimekizumab (Bimzelx) for Psoriasis

- Summary
- Subjects
- Metrics

Abstract

The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx – UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy. Bimekizumab is the first IL-17A/17F antagonist to be approved in the US. It was approved in the European Union for the same indication in 2021.

Keywords

Humans, Psoriasis, Ustekinumab, Antibodies, Monoclonal, Humanized

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average